Summary: H.R.6642 — 115th Congress (2017-2018)All Information (Except Text)

There is one summary for H.R.6642. Bill summaries are authored by CRS.

Shown Here:
Introduced in House (07/31/2018)

This bill terminates certain limitations regarding drug rebates under Medicaid. Currently, the maximum rebate that drug manufacturers must pay under Medicaid for single-source and innovator multiple-source drugs is 100% of the average manufacturer price of the drug. The bill specifies that this limitation only applies to rebate periods that begin before January 1, 2019.